Checked
Alaunos Therapeutics, Inc.
Nasdaq: TCRT · Pharmaceutical Preparations · Fort Lauderdale, FL
- Revenue
- $5K
- -50.0% vs. prior year
- Net income
- -$4.18M
- -83520.0% net margin
- Total assets
- $2.97M
- Diluted EPS
- -$2.20
Company details
As reported to the SEC
- SEC CIK
- 1107421
- Stock
- Nasdaq: TCRT
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- Headquarters
- 501 E Las Olas Blvd, Suite 300, Fort Lauderdale, FL 33301
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Non-accelerated filer, Smaller reporting company
- Phone
- (346) 355-4099
- Employer ID (EIN)
- 84-1475642
- Last annual report
- 03/31/2026
- Last quarterly report
- 08/14/2026
Formerly: ZIOPHARM ONCOLOGY INC (until 01/04/2022); EASYWEB INC (until 09/19/2005)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $5K | $10K | $5K | $2.92M | $398K |
| Operating income | -$4.22M | -$4.81M | -$34.27M | -$35.1M | -$77.55M |
| Net income | -$4.18M | -$4.68M | -$4.68M | -$37.73M | -$78.75M |
| Diluted earnings per share | -$2.20 | -$2.92 | -$21.97 | -$2.61 | -$0.37 |
| Research and development | $1.36M | $362K | $16.28M | $25.02M | $49.64M |
| Total assets | $2.97M | $2.75M | $8.26M | $64.94M | $94.86M |
| Total liabilities | $813K | $692K | $1.96M | $26.38M | $36.81M |
| Shareholders' equity | $2.15M | $2.06M | $6.31M | $38.55M | $58.06M |
| Cash and cash equivalents | $1.39M | $1.09M | $6.06M | $39.06M | $76.05M |
| Long-term debt | Not reported | $0 | $0 | $0 | $16.25M |
| Cash from operations | -$2.87M | -$4.97M | -$30.14M | -$29.23M | -$61.47M |
| Capital expenditures | $98K | $0 | $197K | $216K | $3.32M |
Recent filings
151 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
22 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Alaunos Therapeutics, Inc. in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other pharmaceutical preparations
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Johnson & JohnsonJNJ | New Brunswick, NJ | $94.19B | $26.8B |
| Eli Lilly & CoLLY | Indianapolis, IN | $65.18B | $20.64B |
| Merck & Co., Inc.MRK | Rahway, NJ | $65.01B | $18.25B |
| Pfizer IncPFE | New York, NY | $62.58B | $7.77B |
| AbbVie Inc.ABBV | North Chicago, IL | $61.16B | $4.23B |
| Astrazeneca PLCAZN | Cambridge, United Kingdom | $58.74B | $10.22B |
| Bristol Myers Squibb CoBMY | Princeton, NJ | $48.19B | $7.05B |
| Abbott LaboratoriesABT | Abbott Park, IL | $44.33B | $6.52B |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Alaunos Therapeutics, Inc.'s CIK number?
- Alaunos Therapeutics, Inc.'s SEC Central Index Key (CIK) is 1107421.
- What is Alaunos Therapeutics, Inc.'s stock ticker?
- Alaunos Therapeutics, Inc. trades as Nasdaq: TCRT.
- What was Alaunos Therapeutics, Inc.'s revenue?
- Alaunos Therapeutics, Inc. reported revenue of $5K for the fiscal year ended Dec 31, 2025, -50.0% from the year before.
- When does Alaunos Therapeutics, Inc.'s fiscal year end?
- Alaunos Therapeutics, Inc.'s fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is Alaunos Therapeutics, Inc. headquartered?
- Alaunos Therapeutics, Inc.'s principal executive office on file with the SEC is in Fort Lauderdale, FL.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026